# To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

> **NCT06204991** · PHASE1 · RECRUITING · sponsor: **Inge Marie Svane** · enrollment: 10 (estimated)

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV
- Melanoma

## Interventions

- **BIOLOGICAL:** ADP-TILIL7
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **DRUG:** Proleukin

## Key facts

- **NCT ID:** NCT06204991
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06204991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06204991, "To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06204991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*